Skip to main content
Bildspel: 

Moberg Pharma completes acquisition of U.S. OTC brands from Bayer HealthCare

On December 6, 2013, Moberg Pharma announced the acquisition of three Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. The acquisition has now been completed. The purchase price amounted to 4.8 MUSD.

The acquired portfolio includes Domeboro®, a topical astringent used for relieving itch and minor skin irritations; Vanquish®, an internal analgesic; and Fergon®, an iron supplement. The brands are sold through Moberg’s current channel, primarily in chain drugstores and mass retailers, such as Walmart.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on December 20th, 2013.

For further information, please contact:
Peter Wolpert, CEO, Moberg Pharma AB, telephone: +46 707 35 71 35, e-mail: peter.wolpert@mobergpharma.se
Peter Östling, IR, Moberg Pharma AB, telephone: +46 76 314 09 78, e-mail: peter.ostling@mobergpharma.se

About Moberg Pharma AB                                                                         
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 40 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail™ and Kaprolac®. Kerasal Nail™ (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.